IL307194A - Pharmaceutical compositions comprising zolmitriptan - Google Patents

Pharmaceutical compositions comprising zolmitriptan

Info

Publication number
IL307194A
IL307194A IL307194A IL30719423A IL307194A IL 307194 A IL307194 A IL 307194A IL 307194 A IL307194 A IL 307194A IL 30719423 A IL30719423 A IL 30719423A IL 307194 A IL307194 A IL 307194A
Authority
IL
Israel
Prior art keywords
pharmaceutical preparations
preparations containing
containing zolmitriptan
zolmitriptan
pharmaceutical
Prior art date
Application number
IL307194A
Other languages
English (en)
Hebrew (he)
Inventor
Michael Wood
James Lillie
Original Assignee
Maplight Therapeutics Inc
Michael Wood
James Lillie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maplight Therapeutics Inc, Michael Wood, James Lillie filed Critical Maplight Therapeutics Inc
Publication of IL307194A publication Critical patent/IL307194A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL307194A 2021-03-25 2022-03-24 Pharmaceutical compositions comprising zolmitriptan IL307194A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163165938P 2021-03-25 2021-03-25
US202263306377P 2022-02-03 2022-02-03
PCT/US2022/021738 WO2022204399A1 (en) 2021-03-25 2022-03-24 Pharmaceutical compositions comprising zolmitriptan

Publications (1)

Publication Number Publication Date
IL307194A true IL307194A (en) 2023-11-01

Family

ID=83397893

Family Applications (1)

Application Number Title Priority Date Filing Date
IL307194A IL307194A (en) 2021-03-25 2022-03-24 Pharmaceutical compositions comprising zolmitriptan

Country Status (10)

Country Link
US (1) US20240189240A1 (https=)
EP (1) EP4313037A4 (https=)
JP (1) JP2024512069A (https=)
KR (1) KR20240004330A (https=)
AU (1) AU2022246101A1 (https=)
BR (1) BR112023019407A2 (https=)
CA (1) CA3213383A1 (https=)
IL (1) IL307194A (https=)
MX (1) MX2023011240A (https=)
WO (1) WO2022204399A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117017983B (zh) * 2023-10-09 2023-12-22 中山大学 曲普坦类药物在制备抗感染药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3090743A1 (en) * 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
US20100179202A1 (en) * 2009-01-14 2010-07-15 Ajanta Pharma Limited. Orally disintegrating composition of zolmitriptan
CN104411301B (zh) * 2012-04-18 2018-02-06 康特拉医药公司 适于改善运动障碍治疗的口服药物配方
KR20160117596A (ko) * 2014-02-07 2016-10-10 오스펙스 파마슈티칼스, 인코포레이티드 신규 제약 제제
HUE059559T2 (hu) * 2015-02-25 2022-12-28 Univ California 5HT agonisták az epilepsziás rendellenességek kezelésére
ES3056138T3 (en) * 2019-10-23 2026-02-18 Maplight Therapeutics Inc Methods of treating the symptoms of autism spectrum disorder

Also Published As

Publication number Publication date
BR112023019407A2 (pt) 2023-11-28
AU2022246101A1 (en) 2023-10-12
KR20240004330A (ko) 2024-01-11
MX2023011240A (es) 2024-01-12
JP2024512069A (ja) 2024-03-18
WO2022204399A1 (en) 2022-09-29
EP4313037A4 (en) 2025-02-26
CA3213383A1 (en) 2022-09-29
US20240189240A1 (en) 2024-06-13
EP4313037A1 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
IL284835A (en) Pharmaceutical combination comprising tno155 and ribociclib
EP4045480A4 (en) PHARMACEUTICAL FORMULATIONS
MA56049A (fr) Formulations stabilisées contenant des anticorps anti-angptl3
KR102735988B9 (ko) 치료 항체 제제
IL285674A (en) Pharmaceutical formulations
IL284733A (en) Pharmaceutical delivery compositions and uses thereof
IL282032A (en) Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation
MA55362A (fr) Formulations stabilisées contenant des anticorps anti-il-33
EP3960152A4 (en) Cosmetic preparation
EP3746080A4 (en) PHARMACEUTICAL FORMULATIONS
EP4015001A4 (en) Oral pharmaceutical composition
IL282591A (en) Aminopeptidase a inhibitors and pharmaceutical compositions comprising the same
IL279877A (en) Ivosidenib forms and pharmaceutical compositions
DK4027973T3 (da) Formuleringer til lægemiddeladministration
IL307194A (en) Pharmaceutical compositions comprising zolmitriptan
EP4434969A4 (en) ANTI-SARS-CoV-2 MEDICATION
HUE061877T2 (hu) Ciklosporin-analógok gyógyszerkészítményei
JP1738571S (ja) 薬用パッケージ
IL287443A (en) Dosage regimens for and compositions including anti-rsv antibodies
IL307928A (en) Pharmaceutical compositions comprising picroside
EP3965739C0 (en) DOSAGE FORMULATIONS OF OLEYL PHOSPHOCHOLINE TABLETS
EP4083213A4 (en) Cancer gene therapy drug
CR20220587A (es) Formulaciones farmacéuticas
IL312073A (en) Pharmaceutical compositions of efruxifermin
PL3787596T3 (pl) Ulepszone formulacje farmaceutyczne